Treatment options for melanoma patients progressing post-adjuvant therapy

15 Feb 2021

Adjuvant therapy has been shown to improve recurrence-free survival after complete resection of Stage III and Stage IV melanoma, and there are a number of PBS-subsidised adjuvant therapies available in Australia. Unfortunately, despite receiving adjuvant treatment, around 50% of patients still recur.

In this podcast, medical oncologist at Chris O’Brien Lifehouse Jenny Lee talks to Associate Professor Matteo Carlino, a consultant medical oncologist at Westmead and Blacktown about management of melanoma patients progressing post-adjuvant therapy.

The views expressed in this podcast are the views of the presenters alone and are not necessarily reflective of the views of the sponsor. Please refer to the appropriate product information before prescribing any treatment mentioned in this podcast.


Associate Professor Matteo Carlino has served on advisory boards for Bristol-Myers Squibb, MSD, Amgen, Novartis, Pierre Fabre, Roche, Sanofi, Merck, Ideaya, Regeneron, Nektar, Eisai, Q biotics and honoraria from Bristol-Myers Squibb, MSD, Novartis

Doctor Jenny Lee has received honorarium (including travel support): BMS, AstraZeneca, Novartis, BioRad.

Already a member?

Login to keep reading.

Email me a login link